Truepill hires Sid Viswanathan as next CEO and other digital health workers

truepil tapped Sid Viswanathan as its next CEO. This news comes after the digital pharmacy Financing deal of $142 million in October.

Viswanathan, co-founder of the company, started Truepill in 2016. Since then, he has served as the company’s president. In this new position he will take care of the day-to-day business. He succeeds co-founder Umar Afridi, who will remain involved with the company as a member of the board of directors.

earlier Viswanathan worked in Johnson & Johnson’s Global Operations Leadership Development program and founded CardMunch.

“From the beginning, our vision has been to create a world where healthcare is accessible and convenient for all,” Viswanathan said in a statement. “I am honored to continue to deepen Truepill’s work, partnering with leading organizations to create solutions that raise the bar on consumer expectations and give everyone access to the care they deserve.”


dr. Jay Bhatti was appointed executive director of the Deloitte Center for Health Solutions and the Deloitte Health Equity Institute† Bhatt comes from the American Hospital Association, where he was the senior vice president and chief medical officer.

Previously, Bhatt was on the Department of Northwestern Medicine and Chief Health Officer of the Illinois Health and Hospital Association.

“Growing up, I was front row seat to the challenges many people in underserved communities face, and these early life experiences convinced me not only to become a doctor, but to become someone who could meet the challenge of meeting different populations. treating disadvantaged neighborhoods and helping communities and organizations change their future,” Bhatt said in a statement.

“I am excited to join an organization with a strong legacy of progress, execution and impact, and one with a mission that reflects my values ​​and aspirations to transform the health of our communities and do so at scale.”


French artificial intelligence company Owkin called dr. Vassili Soumelis as his next chief medical officer and Eric Durand as his SVP of data science. Soumelis is a professor at the Université de Paris, coordinator of ImmunAID and a practicing physician.

Durand comes to Owkin after serving as director of data science at Novartis. His new duties include overseeing data science activities at the company.

“I was struck early on by the quality and innovative nature of Owkin’s work,” Durand said in a statement. “Combined with the incredible data asset the company is building through its federated platform, I believe Owkin is uniquely positioned to make a lasting impact on patients.

“Helping the best analytics to influence drug discovery has been my goal for many years, and it’s hard for me to imagine a better place than Owkin to advance this mission. Can’t wait to get started. “